Traitements2programmes
Essais1liés
Publications3liées
SourceDBlocale

Traitements

2
MoléculeIndication / populationPhaseObjectifPaysRésultat
Levodopa/carbidopa solution for SC administrationIn this Phase I/IIa study, the effect of continuous subcutaneous administration of LD/CD solution (ND0612) on the safety and PK profile of LD will be examined. Parkinson Phase 1 À vérifier Israel À vérifier
Levodopa/carbidopa solution for SC administrationIn this Phase I/IIa study, the effect of continuous subcutaneous administration of LD/CD solution (ND0612) on the safety and PK profile of LD will be examined. Parkinson Phase 1 À vérifier Israel À vérifier

Essais cliniques

1
MoléculeIndication / populationPhaseNCTTitreStatut
Levodopa/carbidopa solution for SC administration Parkinson Phase 1 NCT01725802 A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients COMPLETED

Publications

3
MoléculeIndication / populationTitreJournalDate
Levodopa/carbidopa solution for SC administration Isolated extra pontine myelinolysis presenting as acute onset parkinsonism. BMJ case reports
Levodopa/carbidopa solution for SC administration Extrapontine Myelinolysis and Reversible Parkinsonism After Hyponatremia Correction in a Case of Pituitary Adenoma: Hypopituitarism as a Predisposition for Osmotic Demyelination. World neurosurgery
Levodopa/carbidopa solution for SC administration Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Annals of neurology